• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲、非洲、中东和亚洲国家新冠疫苗接种建议演变的叙述性综述

Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia.

作者信息

Spinardi Júlia, Dantas Ana Carolina, Carballo Carolina, Thakkar Karan, Akoury Nadine Al, Kyaw Moe Hein, Del Carmen Morales Castillo Graciela, Srivastava Amit, Sáfadi Marco Aurélio P

机构信息

Vaccine Medical and Scientific Affairs, Pfizer, Rua Alexandre Dumas, 1860, São Paulo, 04717904, Brazil.

Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.

出版信息

Infect Dis Ther. 2023 May;12(5):1237-1264. doi: 10.1007/s40121-023-00804-2. Epub 2023 Apr 25.

DOI:10.1007/s40121-023-00804-2
PMID:37097556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10127189/
Abstract

The rapid rollout of vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic over the past 2 years has resulted in the use of various vaccine platforms and regional differences in COVID-19 vaccine implementation strategies. The aim of this narrative review was to summarize evolving COVID-19 vaccine recommendations in countries in Latin America, Asia, and Africa and the Middle East across various vaccine platforms, age groups, and specific subpopulations. Nuances in primary and booster vaccination schedules were evaluated, and the preliminary impact of such diverse vaccination strategies are discussed, including key vaccine effectiveness data in the era of Omicron-lineage variants. Primary vaccination rates for included Latin American countries were 71-94% for adults and between 41% and 98% for adolescents and children; rates for first booster in adults were 36-85%. Primary vaccination rates for adults in the included Asian countries ranged from 64% in the Philippines to 98% in Malaysia, with corresponding booster rates varying from 9% in India to 78% in Singapore; for adolescents and children, primary vaccination rates ranged from 29% in the Philippines to 93% in Malaysia. Across included African and Middle Eastern countries, primary vaccination rates in adults varied widely from 32% in South Africa to 99% in the United Arab Emirates; booster rates ranged from 5% in South Africa to 60% in Bahrain. Evidence from the regions studied indicates preference of using an mRNA vaccine as a booster on the basis of safety and effectiveness of observed real-world data, especially during circulation of Omicron lineages. Vaccination against COVID-19 remains of paramount importance to reduce the burden of disease; strategies to overcome vaccine inequity, fatigue, hesitancy, and misinformation and to ensure adequate access and supply are also important.

摘要

在过去两年里,为抗击2019冠状病毒病(COVID-19)大流行而迅速推出的疫苗导致了多种疫苗平台的使用以及COVID-19疫苗实施策略的地区差异。本叙述性综述的目的是总结拉丁美洲、亚洲、非洲和中东各国在不同疫苗平台、年龄组和特定亚人群中不断演变的COVID-19疫苗建议。评估了初次和加强疫苗接种计划的细微差别,并讨论了这种多样化疫苗接种策略的初步影响,包括奥密克戎谱系变体时代的关键疫苗有效性数据。纳入研究的拉丁美洲国家成年人的初次疫苗接种率为71%-94%,青少年和儿童的接种率在41%至98%之间;成年人的首次加强接种率为36%-85%。纳入研究的亚洲国家成年人的初次疫苗接种率从菲律宾的64%到马来西亚的98%不等,相应的加强接种率从印度的9%到新加坡的78%不等;青少年和儿童的初次疫苗接种率从菲律宾的29%到马来西亚的93%不等。在纳入研究的非洲和中东国家中,成年人的初次疫苗接种率差异很大,从南非的32%到阿拉伯联合酋长国的99%;加强接种率从南非的5%到巴林的60%不等。来自所研究地区的证据表明,根据观察到的真实世界数据的安全性和有效性,尤其是在奥密克戎谱系传播期间,倾向于使用mRNA疫苗作为加强针。接种COVID-19疫苗对于减轻疾病负担仍然至关重要;克服疫苗不平等、疲劳、犹豫和错误信息以及确保充足的获取和供应的策略也很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/e92c8ce7cc2e/40121_2023_804_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/20f63290c438/40121_2023_804_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/8903106c8305/40121_2023_804_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/e92c8ce7cc2e/40121_2023_804_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/20f63290c438/40121_2023_804_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/8903106c8305/40121_2023_804_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e0e/10229497/e92c8ce7cc2e/40121_2023_804_Fig3_HTML.jpg

相似文献

1
Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia.拉丁美洲、非洲、中东和亚洲国家新冠疫苗接种建议演变的叙述性综述
Infect Dis Ther. 2023 May;12(5):1237-1264. doi: 10.1007/s40121-023-00804-2. Epub 2023 Apr 25.
2
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.关于二价加强针相对于单价加强针或初始疫苗接种周期在 SARS-CoV-2 疫苗功效方面的真实世界证据:叙述性综述。
Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081.
3
The COVID-19 experience in Africa and the Middle East.非洲和中东的 COVID-19 经历。
Ann Med. 2023 Dec;55(1):2222641. doi: 10.1080/07853890.2023.2222641.
4
Self-Reported COVID-19 Vaccine and Booster Acceptance and Hesitancy Among Autistic Adults in Pennsylvania: Cross-Sectional Analysis of Survey Data.宾夕法尼亚州自闭症成年人自我报告的新冠疫苗及加强针接种接受度与犹豫情况:调查数据的横断面分析
JMIR Public Health Surveill. 2024 Aug 28;10:e51054. doi: 10.2196/51054.
5
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.在北欧国家奥密克戎为主导期间,不同异源第三剂疫苗接种方案对严重 COVID-19 的效果比较:基于人群的队列分析。
BMJ. 2023 Jul 24;382:e074325. doi: 10.1136/bmj-2022-074325.
6
The impact of COVID-19 and catch-up strategies on routine childhood vaccine coverage trends in Latin America: A systematic literature review and database analysis.COVID-19 疫情对拉丁美洲常规儿童疫苗接种覆盖率趋势的影响:系统文献回顾和数据库分析。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2102353. doi: 10.1080/21645515.2022.2102353. Epub 2022 Sep 9.
7
COVID-19 vaccine hesitancy in Latin America and Africa: a scoping review.拉丁美洲和非洲的 COVID-19 疫苗犹豫:范围综述。
Cad Saude Publica. 2023 Aug 7;39(8):e00041423. doi: 10.1590/0102-311XPT041423. eCollection 2023.
8
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.同源和异源 COVID-19 加强针在接种 1 剂 Ad.26.COV2.S(强生[詹森])疫苗后的有效性:成人因 COVID-19 前往急诊和紧急护理就诊和住院的情况 - VISION 网络,10 个州,2021 年 12 月至 2022 年 3 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
9
COVID-19 vaccine and booster hesitation around the world: A literature review.全球范围内对COVID-19疫苗及加强针的犹豫态度:一项文献综述
Front Med (Lausanne). 2023 Jan 12;9:1054557. doi: 10.3389/fmed.2022.1054557. eCollection 2022.
10
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.新加坡 12-17 岁青少年中针对 SARS-CoV-2 感染和住院的基础系列和加强针接种的有效性:一项全国队列研究。
Lancet Infect Dis. 2023 Feb;23(2):177-182. doi: 10.1016/S1473-3099(22)00573-4. Epub 2022 Sep 28.

引用本文的文献

1
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.用mRNA、腺病毒或灭活新冠疫苗进行初免的成年人中UB-612异源加强针的安全性和免疫原性:一项随机、活性对照的3期试验。
EClinicalMedicine. 2025 Jul 21;86:103349. doi: 10.1016/j.eclinm.2025.103349. eCollection 2025 Aug.
2
Examining COVID-19 vaccination coverage and acceptability among migrants in transit through Mexico during 2021-2022: Insights from shelter surveys and interviews.2021 - 2022年期间对途经墨西哥的过境移民的新冠疫苗接种覆盖率和可接受性的调查:来自收容所调查和访谈的见解
PLoS One. 2025 Jul 11;20(7):e0324325. doi: 10.1371/journal.pone.0324325. eCollection 2025.
3

本文引用的文献

1
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil.巴西使用同源和异源加强针的灭活新冠疫苗对奥密克戎的有效性。
Nat Commun. 2022 Oct 6;13(1):5536. doi: 10.1038/s41467-022-33169-0.
2
Data capture and sharing in the COVID-19 pandemic: a cause for concern.在 COVID-19 大流行期间的数据采集和共享:令人担忧的问题。
Lancet Digit Health. 2022 Oct;4(10):e748-e756. doi: 10.1016/S2589-7500(22)00147-9.
3
SARS-CoV-2 Omicron and its current known unknowns: A narrative review.SARS-CoV-2 奥密克戎及其当前已知的未知:叙述性综述。
Risk factors for severe COVID-19 outcomes in LATAM countries in the post-vaccination era: an analysis of national surveillance data in Argentina, Brazil, Colombia, and Mexico.疫苗接种后时代拉丁美洲国家严重新冠疫情后果的风险因素:对阿根廷、巴西、哥伦比亚和墨西哥国家监测数据的分析
J Glob Health. 2025 Apr 28;15:04141. doi: 10.7189/jogh.15.04141.
4
Clinical characteristics, SARS-CoV-2 variants, and outcomes of adults hospitalized due to COVID-19 in Latin American countries.拉丁美洲国家因新冠肺炎住院成人的临床特征、新冠病毒变异株及预后情况。
Clinics (Sao Paulo). 2025 Apr 23;80:100648. doi: 10.1016/j.clinsp.2025.100648. eCollection 2025.
5
Anti-Platelet factor 4 immunothrombosis-not just heparin and vaccine triggers.抗血小板因子4免疫性血栓形成——不仅仅是肝素和疫苗引发的。
Res Pract Thromb Haemost. 2025 Mar 12;9(2):102729. doi: 10.1016/j.rpth.2025.102729. eCollection 2025 Feb.
6
Parental hesitancy for pediatric COVID-19 vaccines in Chile.智利父母对儿童新冠疫苗的犹豫态度。
Ther Adv Vaccines Immunother. 2025 Mar 12;13:25151355251322312. doi: 10.1177/25151355251322312. eCollection 2025.
7
Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT.源自疫苗诱导的免疫性血小板减少症和血栓形成(VITT)患者的重组抗PF4抗体有助于VITT的研究和实验室诊断。
Vaccines (Basel). 2024 Dec 24;13(1):3. doi: 10.3390/vaccines13010003.
8
Genomic Evolution of the SARS-CoV-2 Omicron Variant in Córdoba, Argentina (2021-2022): Analysis of Uncommon and Prevalent Spike Mutations.阿根廷科尔多瓦省新冠病毒奥密克戎变种的基因组进化(2021 - 2022年):罕见和常见刺突蛋白突变分析
Viruses. 2024 Dec 3;16(12):1877. doi: 10.3390/v16121877.
9
A systematic literature review on public health and healthcare resources for pandemic preparedness planning.系统文献回顾:大流行准备规划中的公共卫生和医疗资源
BMC Public Health. 2024 Nov 11;24(1):3114. doi: 10.1186/s12889-024-20629-z.
10
Global trends in COVID-19 incidence and case fatality rates (2019-2023): a retrospective analysis.全球 COVID-19 发病率和病死率趋势(2019-2023 年):回顾性分析。
Front Public Health. 2024 Jul 29;12:1355097. doi: 10.3389/fpubh.2024.1355097. eCollection 2024.
Rev Med Virol. 2023 Jan;33(1):e2398. doi: 10.1002/rmv.2398. Epub 2022 Sep 23.
4
Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.BNT162b2疫苗在南非针对奥密克戎亚谱系的有效性和持久性
N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.
5
WHO releases global COVID-19 vaccination strategy update to reach unprotected.世界卫生组织发布全球新冠疫苗接种战略更新,以覆盖未接种人群。
Saudi Med J. 2022 Aug;43(8):976.
6
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Aug 11;387(6):525-532. doi: 10.1056/NEJMoa2203209. Epub 2022 Jul 20.
7
The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of COVID-19 Disease.接种新型冠状病毒疫苗对新冠肺炎疾病结局的影响。
Infect Drug Resist. 2022 Jul 2;15:3477-3489. doi: 10.2147/IDR.S365179. eCollection 2022.
8
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.既往感染和疫苗接种对奥密克戎感染症状的影响。
N Engl J Med. 2022 Jul 7;387(1):21-34. doi: 10.1056/NEJMoa2203965. Epub 2022 Jun 15.
9
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.mRNA 疫苗预防卡塔尔奥密克戎 BA.1 和 BA.2 亚变种对 SARS-CoV-2 的保护持续时间。
Nat Commun. 2022 Jun 2;13(1):3082. doi: 10.1038/s41467-022-30895-3.
10
Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.科兴新冠疫苗在智利奥密克戎疫情期间对 3-5 岁儿童的有效性。
Nat Med. 2022 Jul;28(7):1377-1380. doi: 10.1038/s41591-022-01874-4. Epub 2022 May 23.